Lawson Kroeker Investment Management Inc. NE Sells 1,498 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Lawson Kroeker Investment Management Inc. NE lessened its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 2.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 55,037 shares of the medical research company’s stock after selling 1,498 shares during the quarter. Charles River Laboratories International comprises about 1.9% of Lawson Kroeker Investment Management Inc. NE’s investment portfolio, making the stock its 17th biggest position. Lawson Kroeker Investment Management Inc. NE owned about 0.11% of Charles River Laboratories International worth $10,160,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the company. Versant Capital Management Inc grew its position in Charles River Laboratories International by 1,071.4% in the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock worth $30,000 after purchasing an additional 150 shares during the last quarter. Wolff Wiese Magana LLC acquired a new stake in Charles River Laboratories International in the 3rd quarter worth $32,000. Pinnacle Bancorp Inc. grew its position in Charles River Laboratories International by 52.0% in the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock worth $35,000 after purchasing an additional 65 shares during the last quarter. Assetmark Inc. grew its position in Charles River Laboratories International by 1,153.3% in the 3rd quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock worth $37,000 after purchasing an additional 173 shares during the last quarter. Finally, ORG Wealth Partners LLC acquired a new stake in Charles River Laboratories International in the 4th quarter worth $56,000. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Trading Down 1.2 %

Shares of NYSE CRL opened at $161.68 on Thursday. Charles River Laboratories International, Inc. has a 1-year low of $159.65 and a 1-year high of $275.00. The company has a market cap of $8.27 billion, a PE ratio of 20.24, a P/E/G ratio of 5.94 and a beta of 1.38. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61. The company has a 50-day moving average of $185.35 and a two-hundred day moving average of $196.24.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share for the quarter, topping analysts’ consensus estimates of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The company had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $975.99 million. During the same period in the previous year, the firm posted $2.72 earnings per share. The company’s revenue was down 1.6% on a year-over-year basis. As a group, equities analysts expect that Charles River Laboratories International, Inc. will post 10.18 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

CRL has been the topic of several research analyst reports. Bank of America decreased their price target on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a research report on Friday, December 13th. Evercore ISI lifted their target price on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the company an “in-line” rating in a research report on Thursday, November 7th. The Goldman Sachs Group decreased their target price on shares of Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating on the stock in a research report on Thursday, January 23rd. William Blair lowered shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 22nd. Finally, StockNews.com lowered shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Thursday, November 7th. Three equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat.com, Charles River Laboratories International has an average rating of “Hold” and a consensus price target of $204.38.

Insider Buying and Selling

In related news, Director Richard F. Wallman sold 6,621 shares of the business’s stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the completion of the sale, the director now directly owns 12,386 shares of the company’s stock, valued at $2,676,862.32. The trade was a 34.83 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 1.30% of the stock is currently owned by insiders.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).